Antiatherogenic activity of fungal beauveriolides, inhibitors of lipid droplet accumulation in macrophages.
Beauveriolides I and III, isolated from the culture broth of fungal Beauveria sp. FO-6979, showed potent inhibitory activity of lipid droplet accumulation in primary mouse peritoneal macrophages. The cellular molecular target of this inhibitory activity was studied in macrophages. Beauveriolides I and III strongly inhibited the cholesteryl ester (CE) synthesis with IC(50) values of 0.78 and 0.41 microM, respectively, without showing significant effects on the triacylglycerol and phospholipid synthesis. Furthermore, lysosomal cholesterol metabolism to CE in macrophages was inhibited by the compounds, indicating that the inhibition site lies within steps between cholesterol departure from the lysosome and CE synthesis in the endoplasmic reticulum. Therefore, acyl-CoA:cholesterol acyltransferase (ACAT) activity in the membrane fractions prepared from mouse macrophages was studied, resulting in a dose-dependent inhibition by beauveriolides I and III with IC(50) values of 6.0 and 5.5 microM, respectively. Thus, we showed that the beauveriolides inhibit macrophage ACAT activity specifically, resulting in blockage of the CE synthesis, leading to a reduction of lipid droplets in macrophages. ACAT activity in the membrane fractions prepared from mouse liver and Caco-2 cells was also inhibited, indicating that the beauveriolides block both ACAT-1 and -2. Moreover, beauveriolides I and III exert antiatherogenic activity in both low-density lipoprotein receptor- and apolipoprotein E-knockout mice without any side effects such as diarrhea or cytotoxicity to adrenal tissues as observed for many synthetic ACAT inhibitors. Beauveriolides I and III are the first microbial cyclodepsipeptides having an in vivo antiatherosclerotic effect and show promise as potential lead compounds for antiatherosclerotic agents.
Namatame
Ichiji
I
Kitasato Institute for Life Sciences and Graduate School of Infection Control Sciences, Kitasato University, and Kitasato Institute, Shirokane, Minato-ku, Tokyo 108-8641, Japan.
Tomoda
Hiroshi
H
Ishibashi
Shun
S
Omura
Satoshi
S
D000284:Administration, Oral; D000818:Animals; D001057:Apolipoproteins E / Q000172:deficiency / Q000235:genetics; D001161:Arteriosclerosis / Q000188:drug therapy / Q000378:metabolism; D002788:Cholesterol Esters / Q000096:biosynthesis; D047630:Depsipeptides; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000302:isolation & purification / Q000494:pharmacology; D005260:Female; D006999:Hypocreales / Q000737:chemistry; D000960:Hypolipidemic Agents / Q000008:administration & dosage / Q000302:isolation & purification / Q000494:pharmacology*; D066298:In Vitro Techniques; D050356:Lipid Metabolism; D017737:Macrophages, Peritoneal / Q000187:drug effects* / Q000378:metabolism*; D051379:Mice; D008810:Mice, Inbred C57BL; D008813:Mice, Inbred ICR; D018345:Mice, Knockout; D010456:Peptides, Cyclic / Q000008:administration & dosage / Q000302:isolation & purification / Q000494:pharmacology*; D011973:Receptors, LDL / Q000172:deficiency / Q000235:genetics; D002785:Sterol O-Acyltransferase / Q000037:antagonists & inhibitors
D001057:Apolipoproteins E; D002788:Cholesterol Esters; D047630:Depsipeptides; D004791:Enzyme Inhibitors; D000960:Hypolipidemic Agents; D010456:Peptides, Cyclic; D011973:Receptors, LDL; C013833:beauverolides; D002785:Sterol O-Acyltransferase